ArticleBMC endocrine disorders2025
Biochemical study on microRNAs (miR-410, miR-133 and miR-582) in Egyptian type 1 diabetic patients.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is a complex metabolic disease with numerous consequences that are especially linked to it. Because microRNAs (miRNAs) are produced specifically in the pancreas and remain stable in various bodily fluids, they can be used for early diagnosis as well as tracking the course and severity of the disease. This study examined the serum expression of miR-410, miR-133, and miR-582 in Egyptian patients with Type 1 Diabetes Mellitus.
methodsThere were two groups of 120 participants in this study: 40 healthy children and 80 diabetic children. Samples of venous blood were obtained from every participant. The quantitative real-time PCR (qRT-PCR) method was used to determine the serum expressions of miR-410, miR-133, and miR-582.
resultsOur findings showed a statistically significant difference in the median relative expression levels of miR-410, miR-133, and miR-582 between the T1DM group and the control group. T1DM patients had higher levels of miR-410 (P < .0001), miR- 133 (P = .006), and miR-582 (P < .0001) compared to controls. ROC curve analysis indicated that miR-410, miR-133, and miR-582 can distinguish T1DM patients from healthy subjects. For miR-410, at a cutoff point of 0.0009, sensitivity was 62%, specificity was 80%, and the area under the curve (AUC) was 0.713. For miR-133, the cutoff was 0.0016, with AUC 0.628, sensitivity 63%, and specificity 60%. For miR-582, the cutoff was 0.00028, with AUC 0.668, sensitivity 71.0%, and specificity 50%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.